Dernières nouvelles pour Eisai Co (OTC:ESALF) Stock

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co Ltd

Jefferies analyst Stephen Barker maintained a Hold rating on Eisai Co (ESALF – Research Report) yesterday and set a price target of Yen5,500.00. Th...

Eisai Co (ESALF) Gets a Hold from Jefferies

Eli Lilly CEO told UK health secretary its Alzheimer's treatment could "prevent" disease: FT

Eli Lilly's Alzheimer's drug donanemab rejected for NHS use

Biogen slips as Morgan Stanley downgrades on Leqembi launch

Eisai reports HY results

Eisai Co., Ltd. 2025 Q2 - Results - Earnings Call Presentation

Eisai Co., Ltd. (ESALF) Q2 2025 Earnings Call Transcript

Eisai: Still Relatively Modest Market-Implied Expectations For Leqembi

Biogen gains as Eisai wins EU nod for Alzheimer's drug

Eisai wins orphan drug status for Lenvima for esophageal cancer

BIIB

BRCTF

ESAIY

ESALF

Eisai Co

Comments

Eisai Co

Actualités

Dernières nouvelles pour Eisai Co (OTC:ESALF) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL